Nanjing Qingpu Biotechnology

The firm's business model is centered on addressing unmet clinical needs in the global pain market by developing non-addictive, long-acting, and potent non-opioid analgesics. Its revenue generation is anticipated from the commercialization of its product pipeline and through strategic partnerships with established pharmaceutical companies for drug distribution. Qingpu Biotechnology operates with a global focus, maintaining a headquarters and R&D center in Nanjing, China, and a subsidiary in California, USA, to conduct clinical studies and registration in both markets concurrently.

The company has developed a robust pipeline of over ten drug candidates utilizing several proprietary technology platforms. These include the XisGel® sustained-release gel platform for long-acting injections lasting from days to months, the ETPF® topical skin preparation platform, and technologies for enhancing the solubility of poorly soluble drugs. Its leading product, Putanning™ (Meloxicam Injection II), is a long-acting NSAID for post-operative pain management that requires only once-daily administration. This drug has achieved a significant milestone by receiving market approval from both the U.S. FDA and China's NMPA in 2025. Other pipeline products, such as QP002 and QP004 for post-surgical pain, are in the preclinical phase. The company has secured multiple rounds of funding from investors including Legend Capital, Indaco Capital, and a recent B+ round of over 100 million RMB to accelerate commercialization and R&D efforts.